The market for musculosketal drugs equates to about 14% of the pharma total and is growing at over 7% year on year. Many musculosketal disorders are incurable so that patients will take these pain- and inflammation-reducing drugs either continuously or periodically for life. As their incidence is age-related, the increase in the size of the aging population is one factor driving the growth.